ArticleCancer chemotherapy and pharmacology2020

Phase 1 study of the HSP90 inhibitor onalespib in combination with AT7519, a pan-CDK inhibitor, in patients with advanced solid tumors.

Khanh T Do et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.